menu search

AGN / Allergan Shares Topline Data For Twice Daily Vuity (Pilocarpine) In Blurry Vision Study

Allergan Shares Topline Data For Twice Daily Vuity (Pilocarpine) In Blurry Vision Study
Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia, age-related blurry near vision. The study met its primary efficacy endpoint, improving near vision. Read More
Posted: Apr 5 2022, 14:45
Author Name: Benzinga
Views: 102036

AGN News  

AbbVie's Allergan reaches $2 billion opioid lawsuit settlement - Bloomberg News

By Reuters
July 27, 2022

AbbVie's Allergan reaches $2 billion opioid lawsuit settlement - Bloomberg News

AbbVie Inc's unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid pai more_horizontal

Allergan Shares Topline Data For Twice Daily Vuity (Pilocarpine) In Blurry Vision Study

By Benzinga
April 5, 2022

Allergan Shares Topline Data For Twice Daily Vuity (Pilocarpine) In Blurry Vision Study

Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ophthalmic solution) more_horizontal


Search within

Pages Search Results: